

**IN THE UNITED STATES DISTRICT COURT  
FOR THE EASTERN DISTRICT OF PENNSYLVANIA**

APOTEX, INC.,	:	CIVIL ACTION
Plaintiff,	:	
v.	:	No. 2:06-cv-2768
CEPHALON, INC., <u>et al.</u> ,	:	
Defendants.	:	
<hr/>		
GIANT EAGLE, INC.,	:	CIVIL ACTION
Plaintiff,	:	
v.	:	No. 2:10-cv-5164
CEPHALON, INC., <u>et al.</u> ,	:	
Defendants.	:	
<hr/>		
WALGREEN CO., <u>et al.</u> ,	:	CIVIL ACTION
Plaintiffs,	:	
v.	:	No. 2:09-cv-3956
CEPHALON, INC., <u>et al.</u> ,	:	
Defendants.	:	
<hr/>		
RITE AID CORPORATION, <u>et al.</u> ,	:	CIVIL ACTION
Plaintiffs,	:	
v.	:	No. 2:09-cv-3820
CEPHALON, INC., <u>et al.</u> ,	:	
Defendants.	:	
<hr/>		

## **ORDER**

**AND NOW**, this 8<sup>th</sup> day of June, 2017, in accordance with the accompanying Memorandum Opinion, it is hereby **ORDERED** that the liability portion of the upcoming trial will be divided into two phases. The first phase will involve only proofs regarding the alleged antitrust violations under the rule of reason. If the jury answers the violation questions in Plaintiffs' favor, a second phase involving causation and injury will commence.

It is further **ORDERED** that only during the second causation/injury phase will the jury be informed that the relevant patent was invalidated in a proceeding which occurred after the challenged settlement agreements were executed. If the second phase occurs, the Court will accept the parties' input on how to instruct the jury regarding the prior patent ruling.

**BY THE COURT:**

**/s/ Mitchell S. Goldberg**

---

**Mitchell S. Goldberg, J.**